Drug Giants Show Mixed Earnings (BMY, LLY)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly said it earned $924 million, or $0.83 per share, in the second quarter. That was down from $1.2 billion, or $1.07 per share in the year-earlier period. Analysts polled by Thomson Reuters expected $0.77 per share. Global sales of $5.6 billion were in line with consensus estimates.
Eli Lilly said it now expects full-year 2012 earnings of $3.30 to $3.40 per share, excluding special items. The previous forecast called for EPS of $3.15 to $3.30. The drugmaker raised its outlook due to the favorable impact of a stronger dollar.
Bristol-Myers said its net income in the quarter plunged 28% to $645 million, or $0.38 cents per share. Adjusted EPS of $0.48 was in line with analysts’ expectations. Total revenue fell year-over-year by 18% to $4.44 billion, which also more-or-less matched consensus estimates.
Bristol-Myers said it now expects 2012 earnings per share of $1.78 to $1.88, although its forecast excluding one-time items remains at $1.90 to $2.00 per share.
Eli Lilly is up about 1.2% in premarket trading to $42.50, in a 52-week range of $33.75 to $44.67. Bristol-Myers closed Tuesday at $34.73, in a 52-week range of $25.69 to $36.34. The mean price target on Bristol-Myers is less than 2% higher than that closing price. Eli Lilly’s current price is higher than the mean price target on shares.
Contact [email protected] for any questions or corrections.





